InvestorsHub Logo
Followers 43
Posts 5751
Boards Moderated 0
Alias Born 04/12/2021

Re: None

Friday, 10/21/2022 1:30:15 PM

Friday, October 21, 2022 1:30:15 PM

Post# of 77
Soon I think “4:19p ET 8/15/2022 - Benzinga
NexImmune Highlights FDA Clearance Of IND For NEXI-003 For The Treatment Of HPV-Related Cancers

Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancers
Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22
Clinical updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 4Q22
Company is prioritizing resources to support Company's lead product candidates, NEXI-001 and NEXI-003
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”

my posts are always theory and not financial advice

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NEXI News